Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 204

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 204
---
 the years ended December 31, 2022, and

Innate's corporate office in Luminy, Marseille, France is leased under a finance lease agreement signed in 2008 with Sogebail, a subsidiary of Société Générale, for an aggregate amount of €6.6 million. The lease-financing agreement has a 12-year term. Innate has a purchase option for all of the buildings and land for the lump sum of €1 at the end of the term of the contract on June 9, 2020, which it has exercised. The Company now owns its corporate office in Luminy, Marseille.

Since July 2017, Innate also rents office space in Marseille, France under a commercial lease.

On January 10, 2020, the Company signed an amendment to the lease for the “ Le Virage” building in order to expand its premises. This amendment also extended the duration of the contractual commitment until 2025.

On March 13, 2023, the Company signed an amendment to the lease for "Le Virage Building" in order to reduce the rental area of its premises located in the "Le Virage" building. This amendment has the effect

of reducing the amount of the commitment relating to rent by €685 thousand. The Company remains committed under this contract until June 30, 2025.

C. Research and Development

For a discussion of our research and development activities, see “ Item 4. B - Business Overview” and “ Item 5. A - Operating Results.”

D. Trend Information

For a discussion of trends, see “ Item 4. B - Business Overview,” “ Item 5. A - Operating Results” and “ Item 5. B - Liquidity and Capital Resources.” Other than as disclosed in these sections, we are not aware of any trends, uncertainties, demands, commitments or events since December 31, 2023 that are reasonably likely to have a material effect on our operating revenues, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial conditions.

E. Critical Accounting Estimates.

The Company applies IFRS as issued by the IASB in its primary financial statements (see Note 2 to the Company’s consolidated financial statements included under "Item 18. Financial Statements" of this Annual Report).

Item 6. Directors, Senior Management and Employees.